UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.151

Sortiert nach

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x219-x227

2012

Volltextzugriff (PDF)

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

JNCI : Journal of the National Cancer Institute, 2011-11, Vol.103 (22), p.1656-1664

2011

Volltextzugriff (PDF)

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.75-80

2015

Volltextzugriff (PDF)

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

Endocrine-related cancer, 2001-09, Vol.8 (3), p.191-195

Dowsett, M

2001

Volltextzugriff (PDF)

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Annals of oncology, 2015-08, Vol.26 (8), p.1685-1691

2015

Volltextzugriff (PDF)

Abstract PL1: Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PL1-PL1

Dowsett, M

2022

Volltextzugriff (PDF)

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Annals of oncology, 2006-04, Vol.17 (4), p.584-587

2006

Volltextzugriff (PDF)

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Oncogene, 2010-08, Vol.29 (33), p.4648-4657

2010

Volltextzugriff (PDF)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

JNCI : Journal of the National Cancer Institute, 2008-10, Vol.100 (19), p.1380-1388

2008

Volltextzugriff (PDF)

Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies

The lancet oncology, 2013-09, Vol.14 (10), p.1009-1019

2013

Volltextzugriff (PDF)

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

JNCI : Journal of the National Cancer Institute, 2007-02, Vol.99 (4), p.283-290

2007

Volltextzugriff (PDF)

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Annals of oncology, 2006-05, Vol.17 (5), p.818-826

2006

Volltextzugriff (PDF)

Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer

British journal of cancer, 2012-05, Vol.106 (11), p.1760-1765

2012

Volltextzugriff (PDF)

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Annals of oncology, 2009-12, Vol.20 (12), p.1948-1952

2009

Volltextzugriff (PDF)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study

British journal of cancer, 2015-07, Vol.113 (3), p.390-395

2015

Volltextzugriff (PDF)

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies

British journal of cancer, 2011-08, Vol.105 (5), p.709-722

HORMONES, Endogenous

2011

Volltextzugriff (PDF)

The AURORA initiative for metastatic breast cancer

British journal of cancer, 2014-11, Vol.111 (10), p.1881-1887

2014

Volltextzugriff (PDF)

Abstract ES5-2: Clinical and molecular profiles to identify who is at risk?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.ES5-2-ES5-2

Dowsett, M

2019

Volltextzugriff (PDF)

Healing of a ruptured anterior cruciate ligament and patient-reported outcomes following non-surgical management with a novel bracing protocol

Journal of science and medicine in sport, 2022-11, Vol.25, p.S27

2022

Volltextzugriff (PDF)

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

Endocrine-related cancer, 2011-10, Vol.18 (5), p.565-577

2011

Volltextzugriff (PDF)

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Annals of oncology, 2019-05, Vol.30, p.iii1-iii1

2019

Volltextzugriff (PDF)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.395-400

2017

Volltextzugriff (PDF)

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

British journal of cancer, 2004-05, Vol.90 (12), p.2317-2325

2004

Volltextzugriff (PDF)

Giant reduction of InN surface electron accumulation: compensation of surface donors by Mg dopants

Physical review letters, 2012-12, Vol.109 (24), p.247605-247605, Article 247605

2012

Volltextzugriff (PDF)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846

2017

Volltextzugriff (PDF)

1 – 25 von 1.151

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.057)
Mit Volltextzugriff
(1.064)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Abstract PL1: Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies

The AURORA initiative for metastatic breast cancer

Abstract ES5-2: Clinical and molecular profiles to identify who is at risk?

Healing of a ruptured anterior cruciate ligament and patient-reported outcomes following non-surgical management with a novel bracing protocol

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Giant reduction of InN surface electron accumulation: compensation of surface donors by Mg dopants

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Aktive Filter

Suchergebnisse filtern